X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
DD01 is a proprietary, once-weekly dual agonist of GLP-1 (glucagon-like peptide-1) and glucagon receptors. It is being evaluated for the treatment of adults with non-alcoholic steatohepatitis.
Lead Product(s): DD01
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: DD01
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 02, 2024
Details:
DD01 is a proprietary, long-acting dual agonist of GLP-1 and glucagon receptors with a half-life of 7-8 days in obese/overweight patients with T2D and NAFLD.
Lead Product(s): DD01
Therapeutic Area: Endocrinology Product Name: DD01
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2023
Details:
Proceeds will be used to advance DD01 into a Phase 2 clinical trial for obese patients with both diabetes and nonalcoholic fatty liver disease, continue support of Phase 2 studies of NLY01 in Parkinson’s and Alzheimer’s disease.
Lead Product(s): DD01
Therapeutic Area: Endocrinology Product Name: DD01
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: DS Asset Management
Deal Size: $51.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing October 19, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
